Drug intelligence / Profile preview

HRS-6209 + HRS-8080

Development stage: Unknown
Lead developer: Shandong Suncadia Medicine
Modality: Small Molecules
Administration: Oral

Overview

HRS-6209 + HRS-8080 is an investigational oral combination therapy under clinical development for the treatment of advanced unresectable or metastatic breast cancer. Both components are novel agents developed by Jiangsu HengRui Medicine and Shandong Suncadia Medicine. The combination is being evaluated in phase 1/2 trials to assess safety, pharmacokinetics, and preliminary efficacy in patients with breast cancer who have progressed after standard therapies. The precise mechanisms of action for each agent have not been publicly disclosed as of June 2025; however, both are presumed to be small molecule targeted therapies based on their development context and trial design[2][4][5][7][9].

Targets

ER (Estrogen receptor)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on HRS-6209 + HRS-8080.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-6209 + HRS-8080.

Explore the full profile